Difference between revisions of "Tbo-filgrastim (Granix)"
Jump to navigation
Jump to search
m (PeterYang moved page Tbo-filgrastim (Granix, Neutroval) to Tbo-filgrastim (Granix)) |
(updated content) |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: | + | Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF). Binds to cell surface receptors on hematopoietic cells and stimulates proliferation‚ differentiation, and some end-cell functional activation.<ref name="insert">[http://granixhcp.com/Pdf/prescribing-information.pdf Tbo-filgrastim (Granix) package insert]</ref><ref>[[Media:Tbo-filgrastim.pdf | Tbo-filgrastim (Granix) package insert (locally hosted backup)]]</ref><ref>[http://www.granixhcp.com/ Granix manufacturer's website]</ref> |
<br>Route: SC | <br>Route: SC | ||
<br>Extravasation: no known issues | <br>Extravasation: no known issues | ||
| Line 7: | Line 7: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http:// | + | *[http://granixhcp.com/Pdf/prescribing-information.pdf Tbo-filgrastim (Granix) package insert]<ref name="insert"></ref> |
*[http://www.uptodate.com/contents/filgrastim-patient-drug-information Tbo-filgrastim (Granix) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/filgrastim-patient-drug-information Tbo-filgrastim (Granix) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/filgrastim-patient-drug-information Tbo-filgrastim (Granix) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/filgrastim-patient-drug-information Tbo-filgrastim (Granix) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 8/29/2012: Initial FDA approval | + | *8/29/2012: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm317392.htm Initial FDA approval] "for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia." |
| + | |||
| + | ==Also known as== | ||
| + | Neutroval. | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | [[Category:Drug index]] | ||
[[Category:Hematopoietic growth factors]] | [[Category:Hematopoietic growth factors]] | ||
[[Category:Granulocyte growth factors]] | [[Category:Granulocyte growth factors]] | ||
[[Category:Drugs FDA approved in 2012]] | [[Category:Drugs FDA approved in 2012]] | ||
Revision as of 03:50, 12 October 2014
General information
Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF). Binds to cell surface receptors on hematopoietic cells and stimulates proliferation‚ differentiation, and some end-cell functional activation.[1][2][3]
Route: SC
Extravasation: no known issues
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Tbo-filgrastim (Granix) package insert[1]
- Tbo-filgrastim (Granix) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 8/29/2012: Initial FDA approval "for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia."
Also known as
Neutroval.